ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024
January 03, 2024 08:07 ET
|
ZyVersa Therapeutics
WESTON, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024”
December 18, 2023 08:12 ET
|
ZyVersa Therapeutics
WESTON, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...
ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200
December 14, 2023 07:01 ET
|
ZyVersa Therapeutics
ZyVersa engages CRO, George Clinical, to manage its P2a clinical trial with VAR 200 in Diabetic Kidney Disease expected to begin Q1-2024.
ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes
December 07, 2023 11:20 ET
|
ZyVersa Therapeutics
Plasma NLRP3 inflammasomes are significantly elevated in early-stage diabetic kidney disease, and levels progressively increase as kidney function worsens.
ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering
December 06, 2023 21:00 ET
|
ZyVersa Therapeutics
WESTON, Fla., Dec. 06, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa” or “the Company”), a clinical stage specialty biopharmaceutical company developing...
ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways
December 06, 2023 07:20 ET
|
ZyVersa Therapeutics
AIM2 and NLRP3 inflammasome activation leads to development of atherosclerotic lesions in diabetic mice.
ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock
November 30, 2023 11:30 ET
|
ZyVersa Therapeutics
WESTON, Fla., Nov. 30, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa” or the “Company”), a clinical stage specialty biopharmaceutical company developing...
ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results
November 14, 2023 16:35 ET
|
ZyVersa Therapeutics
Key Corporate Highlights: Progressing toward Q1-2024 initiation of a proof-of-concept clinical trial with Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease...
ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model
November 09, 2023 07:35 ET
|
ZyVersa Therapeutics
NLRP3 inflammasome inhibition attenuates intestinal inflammation and tissue damage, and significantly improves symptoms in IBD animal model.
ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 Activation
November 06, 2023 07:05 ET
|
ZyVersa Therapeutics
Air pollution linked with development and progression of chronic kidney disease that can be attenuated by inhibiting inflammasome NLRP3 activation.